Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Listening...

Search Results

No Results

    Sorry, I don't understand. Please try again

    1. Home/
    2. News/
    3. Health & wellness/
    4. Baby’s first breath: How one landmark program in China has saved 150,000 newborns
    Helping Babies Breath Hi Res

    Baby’s first breath: How one landmark program in China has saved 150,000 newborns

    Sixty seconds. That’s how much time a healthcare professional has to ensure that a newborn takes a first breath in order for that baby to have a healthy start in life.

    But far too often newborns aren’t able to take that first breath on their own.

    It’s a condition known as birth asphyxia—and it’s one of the world’s leading causes of infant mortality. In fact, some 10 million newborns worldwide have difficulty breathing at birth each year. And in China, over 73,000 babies died from the complication in 2004 alone.

    So to help change that alarming statistic, Johnson & Johnson formed a first-of-its-kind public-private partnership with the Chinese government and other professional associations to launch the “Freedom of Breath, Fountain of Life” training program.

    The goal: help prevent birth asphyxia in Chinese hospitals by ensuring that every delivery had at least one person trained in neonatal resuscitation present.

    Today, as the program marks its 10-year anniversary, the initiative has saved an estimated 150,000 newborns across the country.

    And that’s just one heartwarming stat.

    As you’ll see in this infographic, there are more inspiring facts, figures and stories behind the formation of this landmark partnership—and the many children to whom it’s given a healthy start.

    Cina NRP Final Infographic

    null

    More from Johnson & Johnson

    Striving for a cure for multiple myeloma: What HCPs need to know

    Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

    The future of immunology

    Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

    What is inflammation?

    Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.